Ablynx, Merck collaborate

Monday, February 3, 2014

Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies,has entered into a second research collaboration and licensing agreement with a subsidiary of Merck.

[Read More]

Ablynx, Merck expand partnership

Wednesday, November 9, 2011

Ablynx has further expanded its relationship with Merck Serono and entered into a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis. The companies will exploit the unique Nanobody features and will develop multi-specific products, which have extended half-lives.

[Read More]